- Report
- May 2023
- 79 Pages
Global
From €3500EUR$3,975USD£3,039GBP
- Report
- May 2023
- 109 Pages
Global
From €3500EUR$3,975USD£3,039GBP
- Report
- January 2025
- 132 Pages
Global
From €896EUR$950USD£752GBP
- Report
- January 2025
- 132 Pages
Global
From €896EUR$950USD£752GBP
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more